Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | CRHR1 | P34998 | 8/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20072114 | 0.89 | IDH1 (0.39) | IDH1CRHR1CRHR2ALDH1A1HPGD | |
| SCHEMBL21644114 | 0.89 | IDH1 (0.39) | IDH1CRHR1CRHR2ALDH1A1HPGD | |
| SCHEMBL20071887 | 0.89 | NR1H2 (0.34) | SMN1; SMN2DRD4 | |
| SCHEMBL20074041 | 0.89 | NR1H2 (0.34) | SMN1; SMN2DRD4 | |
| SCHEMBL21686495 | 0.89 | PDK2 (0.35) | SMN1; SMN2DRD4 | |
| SCHEMBL21686260 | 0.88 | IDH1 (0.36) | IDH1CRHR1CRHR2ALDH1A1HPGD | |
| SCHEMBL21644417 | 0.88 | IDH1 (0.35) | IDH1CRHR1CRHR2ALDH1A1HPGD | |
| SCHEMBL21644405 | 0.88 | IDH1 (0.37) | IDH1CRHR1CRHR2ALDH1A1HPGD | |
| SCHEMBL21644416 | 0.88 | IDH1 (0.35) | IDH1CRHR1CRHR2ALDH1A1HPGD | |
| SCHEMBL21644402 | 0.88 | IDH1 (0.37) | IDH1CRHR1CRHR2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039951-A1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | NR1H2, NR1H3, NR1H4 | IDH1 1387/4885CRHR1 635/4885CRHR2 1198/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | IDH1 1387/4885CRHR1 635/4885CRHR2 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.